

NeuroSearch A/S  
Pederstrupvej 93  
DK - 2750 Ballerup  
Denmark  
Telephone: +45 4460 8000  
Telefax: +45 4460 8080  
ns@neurosearch.dk  
www.neurosearch.com  
CVR No: DK-12 54 61 06

## Announcement

### NeuroSearch A/S' share capital and voting rights

On 23 January 2008, NeuroSearch increased its share capital with the issue of 185,755 new shares of DKK 20 nominal value each at a price of DKK 319.21 each as milestone payment to the sellers of Carlsson Research AB relating to the start-up of the Phase I study with the drug candidate ACR343.

Pursuant to section 6 of Executive Order no. 1172 of 9 October 2007 on Issuers' Disclosure Obligations, it is hereby announced that at the end of January 2008, the total nominal value of NeuroSearch A/S' share capital is DKK 308,568,840, which is made up of 15,428,442 shares with a nominal value of DKK 20 each, and corresponding to 308,568,840 votes.

Asger Aamund  
Chairman of the Board

### Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.